glp-faq
All FAQs
FAQgeneral

How does retatrutide work?

Retatrutide activates three receptors: GLP-1, GIP, and glucagon. Here's what each one does and why the combination produces more weight loss than dual agonists.

Updated May 18, 2026 · 4 min read

Retatrutide is a triple agonist — a single molecule that activates three different hormone receptors simultaneously: GLP-1, GIP, and glucagon. Each receptor contributes something distinct to weight loss and metabolic regulation. The combination is what makes retatrutide's early trial results notably better than drugs that hit only one or two of those targets.

Receptor 1: GLP-1 (The Foundation)

GLP-1 (glucagon-like peptide-1) is the hormone that all GLP-1 drugs are named after — the same receptor that semaglutide and tirzepatide activate. When stimulated, GLP-1 receptors:

  • Suppress appetite. GLP-1 receptors in the hypothalamus reduce hunger signals and quiet the persistent low-grade preoccupation with food that many people on GLP-1 drugs describe losing ("food noise").
  • Slow gastric emptying. Food physically stays in your stomach longer, so a given meal keeps you fuller for an extended period.
  • Stimulate insulin release in a glucose-dependent way — meaning the pancreas releases insulin when blood sugar is elevated, not constantly. This reduces hypoglycemia risk vs. older diabetes drugs.
  • Suppress glucagon after meals. In healthy metabolism, glucagon rises after meals to maintain blood sugar — GLP-1 dampens this response, preventing post-meal blood sugar spikes.

GLP-1 receptor agonism is the reason semaglutide produces ~15% weight loss. It's the foundation of the retatrutide mechanism.

Receptor 2: GIP (The Amplifier)

GIP (glucose-dependent insulinotropic polypeptide) is the second receptor in tirzepatide and retatrutide. Tirzepatide's superiority over semaglutide is largely explained by adding GIP:

  • Additional appetite suppression via a separate neural pathway from GLP-1. The two receptors appear to work in an additive or synergistic way in the brain's appetite centers.
  • Fat cell regulation. GIP receptors are expressed on adipocytes (fat cells) and appear to affect how fat cells respond to insulin, potentially altering the balance of fat storage vs. fat release.
  • Improved tolerability. GIP agonism may counteract some of GLP-1's nausea at the gut level — one hypothesized reason tirzepatide has a somewhat cleaner tolerability profile than semaglutide at matched weight-loss doses.
  • Complementary insulin secretion that enhances GLP-1's pancreatic effect.

GLP-1 + GIP together explain why tirzepatide produces ~21% weight loss versus semaglutide's ~15%.

Receptor 3: Glucagon (The Metabolic Booster)

The glucagon receptor is what makes retatrutide different from everything before it.

Glucagon is commonly described as insulin's opposing hormone — it raises blood sugar by signaling the liver to release stored glucose. This is why you'd normally not want to activate it in a drug targeting blood sugar or weight. But glucagon has another effect that's less well known: it raises energy expenditure.

Glucagon receptor activation:

  • Stimulates thermogenesis in brown and beige adipose tissue — fat cells that burn energy as heat rather than storing it
  • Promotes lipolysis — the breakdown of stored fat directly, independent of food intake
  • Increases basal metabolic rate — you burn more calories at rest

The elegant pharmacological trick in retatrutide's design: the GLP-1 and GIP components suppress blood glucose, providing a buffer that allows glucagon receptor activation without causing the hyperglycemia you'd normally get from glucagon stimulation. You get the thermogenic and lipolytic benefits of glucagon without the blood sugar spike.

This is the mechanism semaglutide and tirzepatide don't have. They reduce weight by lowering intake. Retatrutide does that and raises output. Two levers instead of one.

Why This Combination Produces More Weight Loss

The three mechanisms compound on each other:

  1. You eat less — appetite is suppressed via both GLP-1 and GIP pathways
  2. You stay full longer — gastric emptying is slowed
  3. Your body burns more calories at baseline — glucagon activation raises resting expenditure and mobilizes stored fat

Phase 2 data showed ~24% mean weight loss at the highest dose (12 mg) over 48 weeks — a meaningfully larger effect than tirzepatide's ~21% at 72 weeks or semaglutide's ~15% at 68 weeks.

The Trade-Off

The glucagon receptor isn't free. Glucagon agonism also:

  • Raises resting heart rate modestly (~2–4 bpm)
  • Can amplify nausea, particularly during the titration period
  • Is an open question for cardiovascular outcomes (the TRIUMPH-2 trial is specifically studying this)

This explains why retatrutide's titration period is longer and more gradual than tirzepatide's — managing the glucagon-driven GI and cardiovascular effects requires a slower ramp.

Retatrutide is not yet FDA-approved. It remains in Phase 3 development (TRIUMPH program). For the detailed trial data, see TRIUMPH-1 decoded and the retatrutide vs tirzepatide comparison.